CU6.ASX RCL.ASX KNO.ASX CTQ.ASX IKE.ASX

Strong First Half Results for ReadCloud

Clarity Pharmaceuticals Starts Phase III AMPLIFY Trial

Clarity Pharmaceuticals has imaged the first patient in its registrational Phase III AMPLIFY trial for 64Cu-SAR-bisPSMA PET/CT, a potential best-in-class diagnostic PSMA agent for prostate cancer. The trial aims to gather data for a New Drug Application and potential commercialisation. Earlier trials have shown 64Cu-SAR-bisPSMA can detect more lesions and identify them earlier than current standard-of-care PSMA PET agents. Clarity is focused on progressing the AMPLIFY trial and building towards potential commercialisation of this promising new diagnostic tool.

ReadCloud Reports Exceptional 1H FY25 Results

ReadCloud Limited has reported strong financial results for the half-year ended 31 March 2025. The company achieved a 13% increase in consolidated Sales & Fee Revenue to $9.16m, driven by 32% growth in the VET-in-schools business and 10% growth in domestic Direct customer eBook Solutions sales. Underlying EBITDA grew 73% to $1.80m, and statutory profit increased 214% to $1.32m. ReadCloud's VET-in-Schools and eBooks businesses, which make up 88% of total revenue, are on track to deliver 15% organic revenue growth in FY25. The company remains debt-free and self-funded, positioning it well to capitalize on the significant opportunities in the school-based education and international schools sectors.

Knosys Unveils Library Tech Growth Strategy

Knosys is unveiling a strategic pivot to become a global-leading provider of library technology solutions. The company plans to simplify its product offerings and prioritize its Libero library management system as the core driver of future growth. Knosys sees significant expansion opportunities for Libero, both geographically and across public, academic, and specialty library segments, with a total addressable market valued at $1.2 billion. The company is executing on an ambitious product roadmap for Libero, introducing new features such as event and resource booking, enhanced discovery and member experience, and a mobile app. Knosys is also investing in AI-powered capabilities to drive efficiency and productivity within library operations.

Careteq Disputes Amended ATO Assessment

Careteq Ltd has been issued amended assessments from the Australian Taxation Office (ATO) regarding its R&D Tax Incentive claims for the past three financial years. The assessments require the repayment of previously received R&D Tax Incentive refunds, totaling $2,956,222.95. Careteq strongly disputes the assessments and plans to lodge a formal objection with the ATO, supported by its legal advisers. The company maintains its strong conviction in the eligibility of its R&D activities for the R&D Tax Incentive scheme.

ikeGPS Reports Strong FY25 Results

ikeGPS Limited has reported its financial results for the 12 months ended 31 March 2025. Revenue from continuing operations increased by 19.2% to $25,155k, while total revenue grew by 18.1% to $25,420k. Net profit/(loss) from continuing operations improved by 8.6% compared to the prior year. The company's annual platform subscription revenue exit run rate grew 48% year-over-year, and subscription revenue is expected to continue increasing strongly at growth levels of 35% or greater in FY26. ikeGPS remains focused on winning and becoming the industry standard in the North American market.